Matches in SemOpenAlex for { <https://semopenalex.org/work/W2200626303> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2200626303 endingPage "TPS223" @default.
- W2200626303 startingPage "TPS223" @default.
- W2200626303 abstract "TPS223 Background: Despite high response rates to MCL induction therapy, relapse is common. Stem cell transplant (SCT) is often utilized, though not curative in most patients (pts), and many are not candidates due to age or comorbidities. Thalidomide and bortezomib have demonstrated activity in MCL. In a phase II trial of rituximab+thalidomide, including thalidomide maintenance, in relapsed/refractory MCL pts, overall/complete response rate (ORR/CR) was 81/31%; median progression free survival (PFS) was 20.4 months; 3-year overall survival (OS) was 75%. In a phase II bortezomib trial with 141 evaluable MCL pts, ORR/CR was 33/8%, with median remission duration (MRD) 9.2 months (mos), and median time to progression (TTP) 6.2 mos. Grade (gr) 3/4 toxicities were peripheral neuropathy (13%), fatigue (12%), and thrombocytopenia (11%). Bortezomib+lenalidomide has been studied in relapsed/refractory myeloma pts, with 61% achieving >minimal response, with MRD of 10.8 mos and acceptable tolerability. Methods: Eligibility criteria: histologically-documented MCL (CD5+, CD23-, cyclin D1+); measurable disease; prior therapy with >1 regimen, including autologous, but not allogeneic, SCT; age ≥18 yrs; no prior radioimmunotherapy; no ≥gr 3 peripheral neuropathy; performance status 0-2. Treatment: Induction: bortezomib 1.3 mg/m2 IV, d1,4,8,11; lenalidomide 20 mg/day PO, d1-14; 21d cycle, 8 cycles. Maintenance (for responders): bortezomib 1.3 mg/m2 IV, d1,8; lenalidomide 15 mg/day PO, d1-14; 21d cycle, till disease progression. Primary endpoint is ORR/CR; secondary endpoints are TTP, disease-free and OS, and correlation of changes in NK/T-cells and plasma cytokines with response. The protocol was modified in 9/09 with separate dose reductions by agent (e.g., myelosuppression-lenalidomide; neuropathy-bortezomib). Accrual: Accrual goal is 54 (49 evaluable) pts. The study was activated in 11/07; a planned interim analysis occurred after 19 patients, with >10 responses required to continue the trial. As of 1/11/11, 48 pts are accrued, with completion anticipated for 6/2011." @default.
- W2200626303 created "2016-06-24" @default.
- W2200626303 creator A5022885582 @default.
- W2200626303 creator A5024891607 @default.
- W2200626303 creator A5037882455 @default.
- W2200626303 creator A5068867603 @default.
- W2200626303 creator A5082606841 @default.
- W2200626303 date "2011-05-20" @default.
- W2200626303 modified "2023-10-07" @default.
- W2200626303 title "A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501)." @default.
- W2200626303 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.tps223" @default.
- W2200626303 hasPublicationYear "2011" @default.
- W2200626303 type Work @default.
- W2200626303 sameAs 2200626303 @default.
- W2200626303 citedByCount "1" @default.
- W2200626303 countsByYear W22006263032012 @default.
- W2200626303 crossrefType "journal-article" @default.
- W2200626303 hasAuthorship W2200626303A5022885582 @default.
- W2200626303 hasAuthorship W2200626303A5024891607 @default.
- W2200626303 hasAuthorship W2200626303A5037882455 @default.
- W2200626303 hasAuthorship W2200626303A5068867603 @default.
- W2200626303 hasAuthorship W2200626303A5082606841 @default.
- W2200626303 hasConcept C126322002 @default.
- W2200626303 hasConcept C141071460 @default.
- W2200626303 hasConcept C143998085 @default.
- W2200626303 hasConcept C197934379 @default.
- W2200626303 hasConcept C2776063141 @default.
- W2200626303 hasConcept C2776364478 @default.
- W2200626303 hasConcept C2776694085 @default.
- W2200626303 hasConcept C2777478702 @default.
- W2200626303 hasConcept C2777525834 @default.
- W2200626303 hasConcept C2778375690 @default.
- W2200626303 hasConcept C2779338263 @default.
- W2200626303 hasConcept C2779609412 @default.
- W2200626303 hasConcept C2780653079 @default.
- W2200626303 hasConcept C2780739268 @default.
- W2200626303 hasConcept C2781413609 @default.
- W2200626303 hasConcept C71924100 @default.
- W2200626303 hasConcept C90924648 @default.
- W2200626303 hasConceptScore W2200626303C126322002 @default.
- W2200626303 hasConceptScore W2200626303C141071460 @default.
- W2200626303 hasConceptScore W2200626303C143998085 @default.
- W2200626303 hasConceptScore W2200626303C197934379 @default.
- W2200626303 hasConceptScore W2200626303C2776063141 @default.
- W2200626303 hasConceptScore W2200626303C2776364478 @default.
- W2200626303 hasConceptScore W2200626303C2776694085 @default.
- W2200626303 hasConceptScore W2200626303C2777478702 @default.
- W2200626303 hasConceptScore W2200626303C2777525834 @default.
- W2200626303 hasConceptScore W2200626303C2778375690 @default.
- W2200626303 hasConceptScore W2200626303C2779338263 @default.
- W2200626303 hasConceptScore W2200626303C2779609412 @default.
- W2200626303 hasConceptScore W2200626303C2780653079 @default.
- W2200626303 hasConceptScore W2200626303C2780739268 @default.
- W2200626303 hasConceptScore W2200626303C2781413609 @default.
- W2200626303 hasConceptScore W2200626303C71924100 @default.
- W2200626303 hasConceptScore W2200626303C90924648 @default.
- W2200626303 hasIssue "15_suppl" @default.
- W2200626303 hasLocation W22006263031 @default.
- W2200626303 hasOpenAccess W2200626303 @default.
- W2200626303 hasPrimaryLocation W22006263031 @default.
- W2200626303 hasRelatedWork W1972519999 @default.
- W2200626303 hasRelatedWork W1999964913 @default.
- W2200626303 hasRelatedWork W2013163224 @default.
- W2200626303 hasRelatedWork W2049852979 @default.
- W2200626303 hasRelatedWork W2136773918 @default.
- W2200626303 hasRelatedWork W2173932373 @default.
- W2200626303 hasRelatedWork W2344741804 @default.
- W2200626303 hasRelatedWork W2527839335 @default.
- W2200626303 hasRelatedWork W2988379501 @default.
- W2200626303 hasRelatedWork W4244042359 @default.
- W2200626303 hasVolume "29" @default.
- W2200626303 isParatext "false" @default.
- W2200626303 isRetracted "false" @default.
- W2200626303 magId "2200626303" @default.
- W2200626303 workType "article" @default.